Three vs. 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: A randomised, double-blind study

Clinical Microbiology and Infection

Volumn 13, Issue 3, 2007, Pages 284-290

  Roede, B M ^a   Bresser, P ^b   El Moussaoui, R ^a   Krouwels, F H ^c   van den Berg, B T J ^d   Hooghiemstra, P M ^e   de Borgie, C A J M ^b   Speelman, P ^a   Bossuyt, P M M ^b   Prins, J M ^a  

^a Center for Infection and Immunity Amsterdam   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c Onze Lieve Vrouwe Hospital   (Netherlands)

^d ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^e BovenIJ Ziekenhuis   (Netherlands)

Author keywords

Amoxycillin clavulanic acid; Antibiotic treatment; Chronic obstructive pulmonary disease; Exacerbation; Respiratory disease; Treatment

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; OXYGEN; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOM; TREATMENT DURATION;

EID: 34247203788     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01638.x     Document Type: Article

References (27)

1. Ball P, Make B. Acute exacerbations of chronic bronchitis: An international comparison. Chest 1998; 113: 199S-204S.
2. Hurd S. The impact of COPD on lung health worldwide: Epidemiology and incidence. Chest 2000; 117: 1S-4S.
3. Sin DD, McAlister FA, Man SF et al. Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003; 290: 2301-2312.
4. Allegra L, Blasi F, de Bernardi B et al. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: A re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther 2001; 14: 149-155.
5. Anthonisen NR, Manfreda J, Warren CP et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
6. Saint S, Bent S, Vittinghoff E et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957-960.
7. Anonymous. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (suppl 1): 1-232.
8. Geijer RM, van Schaijck C, van Weel C et al. NHG-standaard COPD. Behandeling 2001. Huisarts Wet 2001; 44: 207-219.
9. El Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: Randomized, double blind study. BMJ 2006; 332: 1355-1362.
10. Pakistan Multicentre Amoxicillin Short-course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: A multicentre double-blind trial. Lancet 2002; 360: 835-841.
11. Groeneveld K, van Alphen L, Eijk PP et al. Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: The effect of antibiotic treatment on persistence. J Infect Dis 1990; 161: 512-517.
12. Soler M, Lode H, Baldwin R et al. Randomised double-blind comparison of oral gatifloxacin and co-amoxiclav for acute exacerbation of chronic bronchitis. Eur J Clin Microbiol Infect Dis 2003; 22: 144-150.
13. Aubier M, Aldons PM, Leak A et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002; 96: 862-871.
14. Guest N, Langan CE. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 1998; 10: 49-54.
15. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-243.
16. Chow AW, Hall CB, Klein JO et al. Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (suppl 1): S62-S88.
17. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med 1991; 91: 87S-92S.
18. Ram FSF, Rodriguez-Roisin R, Granados-Navarette A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006 CD004403;.
19. Rautakorpi UM, Klaukka T, Honkanen P et al. Antibiotic use by indication: A basis for active antibiotic policy in the community. Scand J Infect Dis 2001; 33: 920-926.
20. Bronzwaer SL, Cars O, Buchholz U et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 2002; 8: 278-282.
21. Finch RG. Introduction: Standards of antibacterial performance. Clin Microbiol Infect 2004; 10 (suppl 2): 1-5.
22. Hsueh PR, Shyr JM, Wu JJ. Changes in macrolide resistance among respiratory pathogens after decreased erythromycin consumption in Taiwan. Clin Microbiol Infect 2006; 12: 296-298.
23. Chen DK, McGeer A, de Azavedo JC et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-239.
24. Felmingham D, Gruneberg RN. The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
25. Gotfried MH, DeAbate CA, Fogarty C et al. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001; 23: 97-107.
26. Hosie J, Quinn P, Smits P et al. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1995; 36: 173-183.
27. Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-513.